WUXI BIOLOGICS (CAYMAN) INC.

Analyst Reco. WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Market Closed - Hong Kong S.E. Other stock markets 09:08:20 26/04/2024 BST			5-day change	1st Jan Change
13.48 ^HKD	+5.81%		+6.81%	-54.46%

04-01	Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	CI
03-27	WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy	03-01	MT
Hong Kong Stocks Rebound Over Unchanged Fed Rates; Wuxi Up 3%	02-01	MT
Nomura Adjusts Wuxi Biologics’ Price Target to HK$58.44 From HK$82.69, Keeps at Buy	12-05	MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$82.69 From HK$86.68, Keeps at Buy	24/07/23	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$86.86 From HK$94.91, Keeps at Buy	21/06/23	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$94.91 From HK$97.78, Keeps at Buy	14/02/23	MT
New energy shares drag China stocks lower, Fed rate-decision jitters weigh	15/09/22	RE
UBS Adjusts Wuxi Biologics’ Price Target to HK$113.12 From HK$110.67, Keeps at Buy	22/08/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy	05/08/22	MT
UBS Adjusts Wuxi Biologics (Cayman)'s Price Target to HK$95.75 From HK$100.87, Keeps at Buy	09/06/22	MT
China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge	20/05/22	RE
UBS Adjusts Wuxi Biologics' Price Target to HK$110.67 From HK$142, Keeps at Buy	29/03/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$100.87 From HK$103.28, Keeps at Buy	24/03/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$103.28 From HK$149.92, Keeps at Buy	17/03/22	MT
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up	11/01/22	RE
WUXI BIOLOGICS CAYMAN : Nomura Adjusts WuXi Biologics' Price Target to HK$116.8 From HK$213.1, Keeps at Buy	29/03/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer